Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension – Page 490

A tiny transparent worm could be the key to finding out how to stop the frailty and ill health which often comes with old age.

British scientists are sending tens of thousands of worms into space in a government backed project to see if two drugs can prevent or slow down muscle wasting brought on by microgravity.

In space, the 1mm long c-elegans worms have nothing to push against to maintain their muscle mass and so quickly start losing strength, mirroring the effect experienced by elderly people back on Earth or those with conditions like muscular dystrophy.

Read more

More information on the search for natural senolytics (that clear the senescent cells and potentially make us younger)- on ficetin, found in abundance for example in strawberries, a newly published study and discussion in the blog of Josh Mitteldorf. But we still would have to consume around 20 kg strawberries for two consecutive days to reach the dose used in the happy longer living mice!

Senolytic drugs have been the most promising near-term anti-aging therapy since the ground-breaking paper by van Deursen of Mayo Clinic published in 2011 . The body accumulates senescent cells as we age, damaged cells that send out signal molecules that in turn modify our biochemistry in a toxic, pro-inflammatory direction. Though the number of such cells is small, the damage they do is great. Van Deursen showed that just getting rid of these cells could increase lifespan of mice by ~25%. But he did it with a trick, using genetically engineered mice in which the senescent cells had a built-in self-destruct switch.

After that, the race was on to find chemical agents that would do the same thing without the genetically engineered self-destruct. They must selectively kill senescent cells, while leaving all other cells unharmed. It’s a tall order, because even a little residual toxicity to normal cells can be quite damaging. Before last week, the two best candidates were FOXO4-DRI and a combination of quercetin with dasatinib .

I’ve written in the past ( here and here ) that senolytic drugs are our best prospect for a near-term lift on the road to anti-aging medicine.

Read more

Thought experiments can be really useful tools to better understand the implications of abstract ideas—especially ideas that are accepted at face value as self-evident truths. In some cases, they resemble proofs by contradiction in that they allow us to see that, if said ideas were true, they would end up clashing with other ideas accepted as non-negotiable principles. What we’re going to try today is something like that.

Crossing into another dimension

Every long-standing rejuvenation advocate has had to put up with people claiming that aging is a good thing on the questionable grounds that it may help to prevent overpopulation, cultural stagnation, the rise of “immortal” dictators, getting bored of far too long lives, and so on. (I was even told by a friend of mine—a truly stalwart advocate who’s anything but afraid of bringing the topic up whenever he gets the chance—that a man once briskly dismissed rejuvenation nonchalantly by saying, “Come on, a little bit of death is all right.” It’s hard not to wonder if he’d think the same if the people close to him were dying.)

Read more

Thoughts on the Eurosymposium on Healthy Ageing held by Heales in Brussels.

When I first learned about the possibility of achieving human rejuvenation through biotechnological means, little did I know that this would lead me to meet many of the central figures in the field during a conference some seven years later—let alone that I would be speaking at the very same event. Yet, I’ve had the privilege to attend the Fourth Eurosymposium on Healthy Ageing (EHA) held in Brussels on November 8–10, an experience that gave me a feel of just how real the prospect of human rejuvenation is.

A friendly, welcoming environment

As EHA was the first conference I’ve ever attended, I didn’t quite know what to expect; given that researchers, activists, and investors from all around the world were invited, I had imagined it would probably be a posh, formal event with violins playing on the background and people in suits and formal dresses discussing topics beyond my comprehension while enjoying champagne. Thankfully, the atmosphere was much more relaxed and informal, elegant but not intimidating, which favored the interaction among participants regardless of their backgrounds—though, alas, the topics discussed were indeed mostly beyond my comprehension, as they involved high-level biochemistry with which I’m nowhere near sufficiently familiar (yet).

Read more

A new study takes a look at the relationship between metabolism, aging, and type 2 diabetes and in particular the mTORC1 protein complex, part of the mTOR pathway.

The mTOR pathway

The mechanistic target of rapamycin (mTOR) pathway is a major part of metabolism and is one of four major pathways that control it; collectively, the four pathways are part of deregulated nutrient sensing, which is one of the aging processes.

Read more

After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.

When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.

Read more